Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Deerfield Management & Brookside Capital Revealed Significant Stakes in Newly Public Dicerna Pharmaceuticals Inc (DRNA)

In a couple of filings with the Securities and Exchange Commission, Deerfield Management, led by James E. Flynn, and Bain Capital’s Brookside Capital reported holding stakes in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), a company that went public a couple of days ago.  Deerfield disclosed holding a total of  2.42 million common shares of the company, while Brookside’s stake amasses 2.34 million shares.

Deerfield obtained the securities through the conversion of around 1.43 million Series C Preferred Stock and the acquisition of additional shares at a price of $15 apiece.

Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), a biopharmaceutical company that focuses on treating rare inherited diseases related to the liver and for cancer, offered 6.0 million shares in its initial public offering at a price of $14.0 per share.

The company has partnered with Kyowa Hakko Kirin Co., Ltd. (KHK) for two of its oncology development programs. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) expects to receive clinical, regulatory and commercialization milestone payments for each of its product candidate under research collaboration and license agreement with KHK, of up to $110.0 million.

RA Capital Healthcare Fund, an affiliate fund of the Peter Kolchinsky‘s Ra Capital Management is also a significant shareholder of Dicerna, holding around 1.43 million shares prior to the IPO.

Deerfield Management focuses on investment companies that specialize in managing hostile takeovers, funding R&D, corporate transitions and financial advisory services.

A couple of months ago, Deerfield Management initiated a passive stake in Horizon Pharma Inc (NASDAQ:HZNP), and revealed owning 4.4 million shares. It also upped its stake in Universal American Corporation (NYSE:UAM) to 4.4 million shares, from 2.9 million shares, and boosted its position in Capital Senior Living Corporation (NYSE:CSU) to 1.8 million shares from 1.1 million shares held earlier.

Brookside Capital is a long/short public equities fund, using fundamental analysis as well as industry and competitive, it invests across all economic sectors.

Brookside Capital held 2.28 million shares of Monsanto Company (NYSE:MON) at the end of the third quarter of 2013. The fund was also bullish on Youku Tudou Inc (ADR) (NYSE:YOKU), and held 8.15 million shares at the end of the third quarter.

Disclosure: none

Recommended reading:

Michael Messner’s Seminole Capital Top Picks From the Latest 13F

Hedge Fund Highlights: Jeffrey Altman, Seth Klarman & Ken Griffin

Sanford J. Colen Sends Letter To Board of MicroStrategy (MSTR); Wants Investor Communication Program

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!